PROpel study backs Lynparza combo in first-line prostate cancerAstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a Share XPROpel study backs Lynparza combo in first-line prostate cancerhttps://pharmaphorum.com/news/propel-study-backs-lynparza-combo-in-first-line-prostate-cancer/
AZ’s COVID-19 jab sales top $1.2bn, but come at a lossAstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in Share XAZ’s COVID-19 jab sales top $1.2bn, but come at a losshttps://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/
ASCO21: Lynparza aces adjuvant breast cancer therapy trialAstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer Share XASCO21: Lynparza aces adjuvant breast cancer therapy trialhttps://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
NICE says no to AZ’s Lynparza for prostate cancerNHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they Share XNICE says no to AZ’s Lynparza for prostate cancerhttps://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/
Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
AZ’s cediranib falls short again in ovarian cancer combinationAstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it Share XAZ’s cediranib falls short again in ovarian cancer combinationhttps://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/
AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
